Dengue en el Servicio de Urgencias: Puntos de buena práctica clínica
Dengue en el Servicio de Urgencias: Puntos de buena práctica clínica
##plugins.themes.bootstrap3.article.sidebar##
PDF (Español (España))
FLIP
##plugins.themes.bootstrap3.article.main##
El dengue es una enfermedad viral transmitida a los humanos principalmente por mosquitos del género Aedes, en particular
Aedes aegypti. Originario de áreas tropicales y subtropicales, su prevalencia ha aumentado drásticamente en las últimas
décadas, convirtiéndose en una preocupación de salud pública global. La infección puede ser asintomática o manifestarse
con una amplia variedad de síntomas. Sin embargo, en algunos casos, puede evolucionar a formas más graves, que se
asociación a una importante morbimortalidad si no se tratan adecuadamente. El virus del dengue tiene cuatro serotipos
distintos (DEN-1-DEN-4). Una infección proporciona inmunidad de por vida contra ese serotipo en particular, pero no contra
los otros. Además, esta descrito que una infección previa puede incrementar el riesgo de desarrollar las formas graves de
la enfermedad si la persona es infectada nuevamente por un serotipo diferente. Actualmente, no existe un tratamiento
específico para el dengue, siendo el manejo clínico centrado en aliviar los síntomas, detección de paciente con riesgo de
presentar formas graves y manejo oportuno de las misma. Las estrategias de prevención incluidas las vacunas se muestran
como una medida valiosa para reducir el impacto del dengue en las comunidades afectadas.
Downloads
##plugins.themes.bootstrap3.article.details##
Whitehorn J, Kien DTH, Nguyen NM, Nguyen HL, Kyrylos PP, Carrington LB, et al.
Comparative susceptibility of aedes albopictus and aedes aegypti to dengue virus infection after feeding on blood of viremic
humans: Implications for public health. Journal of Infectious Diseases. 2015 Oct 15;212(8):1182–90.
Danis-Lozano R, Díaz-González EE, Malo-García IR, Rodríguez MH, Ramos-Castañeda J, Juárez-Palma L, et al. Vertical
transmission of dengue virus in Aedes aegypti and its role in the epidemiological persistence of dengue in Central and Southern
Mexico. Tropical Medicine and International Health. 2019 Nov 1;24(11):1311–9.
Reveiz L. Evidence synthesis: guidelines for diagnosis and treatment of dengue, chikungunya, and zika in the Region of the
Americas. Revista Panamericana de Salud Publica/Pan American Journal of Public Health. 2022;46.
Buchs A, Conde A, Frank A, Gottet C, Hedrich N, Lovey T, et al. The threat of dengue in Europe. Vols. 49–50, New Microbes and
New Infections. Elsevier Ltd; 2022.
Brady OJ, Hay SI. Annual Review of Entomology The Global Expansion of Dengue: How Aedes aegypti Mosquitoes Enabled the
First Pandemic Arbovirus. 2019; Available from: https://doi.org/10.1146/annurev-ento-011019-
Messina JP, Brady OJ, Golding N, Kraemer MUG, Wint GRW, Ray SE, et al. The current and future global distribution and
population at risk of dengue. Nat Microbiol. 2019 Sep 1;4(9):1508–15.
Thomson MC, Stanberry LR. Climate Change and Vectorborne Diseases. New England Journal of Medicine. 2022 Nov
;387(21):1969–78.
Castillo-Méndez M, Valverde-Garduño V. Aedes aegypti Immune Response and Its Potential Impact on Dengue Virus
Transmission. Viral Immunol. 2020 Jan 1;33(1):38–47.
R.F.S Revista Facultad de Salud Dengue en el Servicio de Urgencias: Puntos de buena práctica clínica.
Número suplementar, diciembre 2023: 136-160
R.F.S. Revista Facultad de Salud 159
Lizuain AA, Maffey L, Garzón M, Leporace M, Soto D, Diaz P, et al. Larval Competition between Aedes albopictus and Aedes
aegypti (Diptera: Culicidae) in Argentina: Coexistence and Implications in the Distribution of the Asian Tiger Mosquito. J Med
Entomol. 2022 Sep 1;59(5):1636–45.
Organización Panamericana de la Salud / Organización Mundial de la Salud. Actualización Epidemiológica: Dengue en la Región
de las Américas. 5 de julio de 2023. Washington, D.C. OPS/OMS. 2023 [Internet]. Available from: https://opendata.paho.org/es
Instituto Nacional de Salud. Boletín Epidemiológico Semanas: Semana Epidemiológica 33 del 13 al 19 de Agosto de 2023.
Colombia Potencia de Vida. 2023.
Mustafa MS, Rasotgi V, Jain S, Gupta V. Discovery of fifth serotype of dengue virus (denv-5): A new public health dilemma in
dengue control. Vol. 71, Medical Journal Armed Forces India. Medical Journal Armed Forces India; 2015. p. 67–70.
Kuhn RJ, Zhang W, Rossmann MG, Pletnev S V, Corver J, Lenches E, et al. Structure of Dengue Virus: Implications for
Flavivirus Organization, Maturation, and Fusion. Vol. 108, Cell. 2002.
Khetarpal N, Khanna I. Dengue Fever: Causes, Complications, and Vaccine Strategies. Vol. 2016, Journal of Immunology
Research. Hindawi Publishing Corporation; 2016.
Chan M, Johansson MA. The Incubation Periods of Dengue Viruses. PLoS One. 2012 Nov 30;7(11).
Guzman MG, Gubler DJ, Izquierdo A, Martinez E, Halstead SB. Dengue infection. Nat Rev Dis Primers. 2016 Aug 18;2.
Chen HR, Lai YC, Yeh TM. Dengue virus non-structural protein 1: A pathogenic factor, therapeutic target, and vaccine candidate.
Vol. 25, Journal of Biomedical Science. BioMed Central Ltd.; 2018.
Tejo AM, Hamasaki DT, Menezes LM, Ho YL. Severe dengue in the intensive care unit.
Journal of Intensive Medicine. Chinese Medical Association; 2023.
Rey FA, Stiasny K, Vaney M, Dellarole M, Heinz FX. The bright and the dark side of human antibody responses to flaviviruses:
lessons for vaccine design. EMBO Rep. 2018 Feb;19(2):206–24.
Roy SK, Bhattacharjee S. Dengue virus: Epidemiology, biology, and disease aetiology. Vol. 67, Canadian Journal of
Microbiology. Canadian Science Publishing; 2021. p. 687–702.
Meuren LM, Prestes EB, Papa MP, de Carvalho LRP, Mustafá YM, da Costa LS, et al. Infection of Endothelial Cells by Dengue
Virus Induces ROS Production by Different Sources Affecting Virus Replication, Cellular Activation, Death and Vascular
Permeability. Front Immunol. 2022 Feb 2;13.
Sekaran SD, Ismail AA, Thergarajan G, Chandramathi S, Rahman SKH, Mani RR, et al. Host immune response against DENV
and ZIKV infections. Vol. 12, Frontiers in Cellular and Infection Microbiology. Frontiers Media S.A.; 2022.
Beatty PR, Puerta-Guardo H, Killingbeck SS, Glasner DR, Hopkins K, Harris E. Dengue virus NS1 triggers endothelial
permeability and vascular leak that is prevented by NS1 vaccination [Internet]. Available from:
www.ScienceTranslationalMedicine.org
Dib PRB, Quirino-Teixeira AC, Merij LB, Pinheiro MBM, Rozini SV, Andrade FB, et al. Innate immune receptors in platelets and
platelet-leukocyte interactions. Vol. 108, Journal of Leukocyte Biology. John Wiley and Sons Inc; 2020. p. 1157–82.
Chuansumrit A, Chaiyaratana W. Hemostatic derangement in dengue hemorrhagic fever. Vol. 133, Thrombosis Research. 2014.
p. 10–6.
Anders KL, Nguyet NM, Chau NVV, Hung NT, Thuy TT, Lien LB, et al. Epidemiological factors associated with dengue shock
syndrome and mortality in hospitalized dengue patients in Ho Chi Minh City, Vietnam. American Journal of Tropical Medicine and
Hygiene. 2011;84(1):127–34.
Guzman MG, Kouri G, Bravo J, Valdes L, Susanavazquez ( ’, Halsteadt3 SB. Original Report Effect of age on outcome of
secondary dengue 2 infections.
Grange L, Simon-Loriere E, Sakuntabhai A, Gresh L, Paul R, Harris E. Epidemiological factors associated with high global
frequency of inapparent dengue virus infections Microbial Immunology. 2014; Available from:
www.frontiersin.org:www.frontiersin.org
Agrawal V, Dinh PC, Fung C, Monahan PO, Althouse SK, Norton K, et al. Adverse Health Outcomes among U.S. Testicular
Cancer Survivors after Cisplatin-Based Chemotherapy vs. Surgical Management. Available from:
https://academic.oup.com/jncics/advance-articleabstract/doi/10.1093/jncics/pkz079/5583763
Wong JM, Adams LE, Durbin AP, Muñoz-Jordán JL, Poehling KA, Sánchez-González LM, et al. Dengue: A Growing Problem
With New Interventions. Vol. 149, Pediatrics. NLM (Medline); 2022.
R.F.S Revista Facultad de Salud Dengue en el Servicio de Urgencias: Puntos de buena práctica clínica.
Número suplementar, diciembre 2023: 136-160
R.F.S. Revista Facultad de Salud 160
Organización Panamericana de la Salud. Dengue: guías para la atención de enfermos en la Región de las Américas. 2.ed.
Washington, DC: OPS, 2016.
Wilder-Smith A, Ooi EE, Horstick O, Wills B. Dengue. Vol. 393, The Lancet. Lancet Publishing Group; 2019. p. 350–63.
Lee TH, Lee LK, Lye DC, Leo YS. Current management of severe dengue infection. Vol. 15, Expert Review of Anti-Infective
Therapy. Taylor and Francis Ltd; 2017. p. 67–78.
Muller DA, Depelsenaire ACI, Young PR. Clinical and laboratory diagnosis of dengue virus infection. Journal of Infectious
Diseases. 2017;215:S89–95.
García G, González N, Pérez AB, Sierra B, Aguirre E, Rizo D, et al. Long-term persistence of clinical symptoms in dengueinfected persons and its association with immunological disorders. International Journal of Infectious Diseases. 2011 Jan;15(1).
Dengue: guidelines for diagnosis, treatment, prevention and control: new edition [Internet]. Available from: www.who.int/tdr
Parkash O, Shueb RH. Diagnosis of dengue infection using conventional and biosensor based techniques. Vol. 7, Viruses. MDPI
AG; 2015. p. 5410–27.
Kok BH, Lim HT, Lim CP, Lai NS, Leow CY, Leow CH. Dengue virus infection – a review of pathogenesis, vaccines, diagnosis
and therapy. Vol. 324, Virus Research. Elsevier B.V.; 2023.
Carod-Artal FJ, Wichmann O, Farrar J, Gascón J. Neurological complications of dengue virus infection. Vol. 12, The Lancet
Neurology. 2013. p. 906–19.
Sejvar JJ. Neurological manifestations of dengue virus infection. In: Dengue and Dengue Hemorrhagic Fever: Second Edition.
CABI International; 2014. p. 145–67.
Burdmann EA. Flaviviruses and Kidney Diseases. Vol. 26, Advances in Chronic Kidney Disease. W.B. Saunders; 2019. p. 198–
Karras A, Hermine O. Syndrome d’activation macrophagique Hemophagocytic syndrome
[Internet]. 2002. Available from: www.elsevier.com/locate/revmed
Lin RJ, Lee TH, Leo YS. Dengue in the elderly: a review. Vol. 15, Expert Review of AntiInfective Therapy. Taylor and Francis Ltd;
p. 729–35.
Martinez-Gutierrez M, Correa-Londoño LA, Castellanos JE, Gallego-Gómez JC, Osorio JE. Lovastatin delays infection and
increases survival rates in AG129 mice infected with dengue virus serotype 2. PLoS One. 2014 Feb 21;9(2).
Martínez-Gutierrez M, Castellanos JE, Gallego-Gómez JC. Statins reduce dengue virus production via decreased virion
assembly. Intervirology. 2011 Jun;54(4):202–16.
Chia PY, Htun HL, Ling WP, Leo YS, Yeo TW, Lye DCB. Hyperlipidemia, statin use and dengue severity. Sci Rep. 2018 Dec
;8(1).
Reveiz L. Evidence synthesis: guidelines for diagnosis and treatment of dengue, chikungunya, and zika in the Region of the
Americas. Revista Panamericana de Salud Publica/Pan American Journal of Public Health. 2022;46.
Organització Mundial de la Salut. World Health Organization & UNICEF/UNDP/World Bank/WHO. Special Programme for
Research and Training in Tropical Diseases. Handbook for clinical management of dengue. Switzerland: World Health
Organization; 2012.
Assir MZK, Kamran U, Ahmad HI, Bashir S, Mansoor H, Anees S Bin, et al. Effectiveness of platelet transfusion in dengue fever:
A randomized controlled trial. Transfusion Medicine and Hemotherapy. 2013 Oct;40(5):362–8.
Lye DC, Archuleta S, Syed-Omar SF, Low JG, Oh HM, Wei Y, et al. Prophylactic platelet transfusion plus supportive care versus
supportive care alone in adults with dengue and thrombocytopenia: a multicentre, open-label, randomised, superiority trial. The
Lancet. 2017 Apr 22;389(10079):1611–8.
Silva JP, Fernandez-Sesma A. Challenges on the development of a dengue vaccine: a comprehensive review of the state of the
art. Vol. 104, Journal of General Virology. Microbiology Society; 2023.
Villar L, Dayan GH, Arredondo-García JL, Rivera DM, Cunha R, Deseda C, et al. Efficacy of a Tetravalent Dengue Vaccine in
Children in Latin America. New England Journal of Medicine. 2015 Jan 8;372(2):113–23.
Hou J, Ye W, Chen J. Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines. Vol. 13, Frontiers
in Immunology. Frontiers Media S.A.; 2022.
